Isomark's breath biomarker pre-symptomatically detects severe infections and tracks, in near real-time, a patient’s individualized response to treatment.
Isomark developed a revolutionary technology that detects infections up to 2 days before standard methods. The initial target for Isomark is hospital-acquired infections (HAI) in the intensive care unit. Early detection of infections saves lives and money—it has been estimated HAIs cost the U.S. healthcare system more than $35 billion annually . Changes to the health care industry are driving hospitals to reduce costs and improve patient care.